Improving care for patients with cardiac amyloidosis has emerged as one of the hottest topics in cardiology. Pfizer helped kickstart that trend in 2019 when it gained FDA approval for two separate medications for the rare, but potentially fatal disease. 

Advanced AI models can evaluate a patient's heart failure risk using 12-lead ECG data—but there is still some room for improvement. 

The company's trademark offering has now been used to evaluate one quarter of a million patients. 

Cardiology makes up 10% of the 692 market-cleared clinical AI algorithms in the FDA’s latest update on the number of patient-facing AI now commercialized in the U.S. Experts share their thoughts on how it is being used.

AI-based prediction models have shown significant promise, but many are still flawed in a way that limits their value. 

The funds are expected to go toward bringing in new employees and accelerating the development of a new cardiac imaging offering. 

Rad Partners' Nina Kottler, MD, explains what practices should consider when assessing artificial intelligence solutions in an era where there is little reimbursement.  
 

CCTA has seen rapid adoption and growth over the past two years, and RSNA vendors fed that trend with new product launches.